Abbott Laboratories (ABT) received a 77% rating from Validea's P/B Growth Investor model, based on Partha Mohanram's strategy for identifying low book-to-market stocks with sustained future growth. As a large-cap medical equipment and supplies company, ABT passed most key fundamental criteria like return on assets and cash flow, though it failed the advertising and R&D to assets tests. This rating, just shy of the 80% 'some interest' threshold, indicates strong underlying growth characteristics according to this academically-derived model.
Abbott Laboratories (ABT) scored 77% on Validea's P/B Growth Investor model, a framework derived from Partha Mohanram's academic research designed to identify low book-to-market stocks with potential for sustained growth. This rating places ABT just below the 80% threshold that typically indicates model interest, suggesting a strong but not top-tier profile according to this specific strategy. The company demonstrates robust underlying fundamentals, passing key tests for Book/Market Ratio, Return on Assets (ROA), and Cash Flow from Operations to Assets, as well as stability metrics like ROA and sales variance. However, the analysis also flagged weaknesses, as ABT failed the model's criteria for both Advertising to Assets and Research and Development to Assets. This mixed result indicates that while ABT exhibits many characteristics of a quality growth company, its investment levels in advertising and R&D do not align with the specific profile of a "winner" as defined by the Mohanram model.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
